Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248872 | 0.86 | PRKDC (0.49) | MAPTHPGDEGFRSRCKDR | |
| SCHEMBL249906 | 0.84 | MEN1 (0.46) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL248993 | 0.81 | EGFR (0.43) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL31554583 | 0.79 | ABCG2 (0.48) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL168459 | 0.78 | EGFR (0.49) | EGFRSRCKDR | |
| SCHEMBL168494 | 0.77 | PIN1 (0.49) | — | |
| SCHEMBL31554570 | 0.77 | PIN1 (0.49) | — | |
| SCHEMBL5546245 | 0.72 | MEN1 (0.48) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL3489608 | 0.72 | MEN1 (0.52) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL6766242 | 0.72 | MEN1 (0.52) | MEN1KMT2AMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588457-B1 | PYRAZOLOQUINOLINE DERIVATIVES AS DNA-PK INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8802712-B2 | Pyrazoloquinolines | MERCK PATENT GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-20130150359-A1 | PYRAZOLOQUINOLINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-13 | — | — | US | disclosed |
| EP-2588457-A1 | PYRAZOLO-QUINOLINES | Merck Patent GmbH (DE) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012000632-A1 | PYRAZOLO-QUINOLINES | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150359-A1 | PYRAZOLOQUINOLINES | PLK1, PKN3, PKN1 | MEN1 624/4885KMT2A 2983/4885MAPT 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.